Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK NHS review finds benefit in combining PET/CT to assess breast cancer recurrence

This article was originally published in Clinica

Executive Summary

A review for the UK’s National Health Service of the use of positron emission tomography (PET) and computed tomography (CT) in prognosing breast cancer recurrence has found that the combination of the two technologies “offers improved diagnostic accuracy compared to conventional imaging tests”. However, “uncertainty remains around its use as a replacement for, rather than as an add-on to, existing technologies”, concluded a team of researchers from the West Midlands Health Technology Assessment Collaboration (WMHTAC) at the University of Birmingham. The systematic review, which appears in the current issue of the journal Health Technology Assessment, was conducted on behalf of the Evaluation, Trials and Studies Coordinating Centre (NETSCC) of the National Institute for Health Research (NIHR).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT096003

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel